发表机构
Marathon Fusion（马拉松融合公司）
机构由 AI 辅助整理，请以论文原文为准。AI 中文总结
提出两阶段法利用高富集钆-150靶材规模化生产铽-149，以解决靶向α疗法供应瓶颈，通过中子或质子途径实现临床级产量。
AI 中文摘要
我们提出了一种两阶段生产方法，以克服α发射体$^{149\mathrm{g}}$Tb（一种有望用于靶向α疗法（TAT）的候选核素，目前尚无全球可扩展的生产途径）的现有供应限制。尽管$^{150}$Gd(p,2n)$^{149\mathrm{g}}$Tb反应截面的实验测量尚待进行，但所提出的方法可在现成的质子回旋加速器上以临床规模及更大规模生产$^{149\mathrm{g}}$Tb，这得益于已灭绝但长寿命同位素$^{150}$Gd的生产，$^{150}$Gd是一种纯α发射体，半衰期为179万年。第一阶段通过用能量≥10 MeV的质子、中子或光子辐照天然Eu或富集$^{151}$Eu来生成$^{150}$Gd原料。第二阶段通过用能量≥14 MeV的质子驱动$^{150}$Gd(p,2n)$^{149\mathrm{g}}$Tb反应，从制备的$^{150}$Gd靶材生产$^{149\mathrm{g}}$Tb，全球超过700台已报道的回旋加速器均可提供该能量。快速聚变中子似乎为$^{150}$Gd生产提供了最具可扩展性的途径：即使考虑到1 GBq的大剂量$^{149\mathrm{g}}$Tb和每年4000万次给药，我们估计这仅需6.8兆瓦稳态氘-氚聚变功率产生的中子即可生产所需的$^{150}$Gd，远低于未来十年预期的产能。如果此处描述的路线得到验证，将使$^{149\mathrm{g}}$Tb的供应达到支持基于$^{149\mathrm{g}}$Tb的TAT临床开发所需的规模。
英文摘要
We propose a two-stage production method to overcome existing supply-constraints for the alpha-emitter $^{149\mathrm{g}}$Tb, a promising candidate for Targeted Alpha Therapy (TAT) with no existing globally scalable production pathway. Although awaiting experimental measurement of the $^{150}$Gd(p,2n)$^{149\mathrm{g}}$Tb cross section, the proposed method could produce $^{149\mathrm{g}}$Tb at clinical scale and beyond on readily available proton cyclotrons, enabled by production of the extinct but long-lived isotope $^{150}$Gd, a pure alpha emitter with a 1.79 million year half-life. Stage one generates $^{150}$Gd feedstock by irradiating natural Eu or enriched $^{151}$Eu with $\gtrsim$10 MeV protons, neutrons or photons. Stage two produces $^{149\mathrm{g}}$Tb from fabricated $^{150}$Gd targets by driving the $^{150}$Gd(p,2n)$^{149\mathrm{g}}$Tb reaction with $\gtrsim$14 MeV protons, accessible on over 700 reported cyclotrons worldwide. Fast fusion neutrons appear to offer the most scalable pathway for $^{150}$Gd production: even with a large $^{149 \mathrm{g}}$Tb dose size of 1 GBq and 40 million administered doses/yr, we estimate this would require neutrons produced by only 6.8 megawatts of steady-state deuterium-tritium power to produce the required $^{150}$Gd, far below expected capacity in the next decade. The route described here, if validated, would enable $^{149\mathrm{g}}$Tb supply at the scale needed to support clinical development of $^{149\mathrm{g}}$Tb-based TAT.
Comments61 pages, 25 figures
